Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

11-01-2018 | Non-small-cell lung cancer | Article

Clinical Impact and Risk Factors for Skeletal Muscle Loss After Complete Resection of Early Non-small Cell Lung Cancer

Journal: Annals of Surgical Oncology

Authors: Shinkichi Takamori, MD, Gouji Toyokawa, PhD, Tatsuro Okamoto, PhD, Mototsugu Shimokawa, PhD, Fumihiko Kinoshita, MD, Yuka Kozuma, MD, Taichi Matsubara, MD, Naoki Haratake, MD, Takaki Akamine, MD, Kazuki Takada, PhD, Masakazu Katsura, MD, Fumihiko Hirai, PhD, Fumihiro Shoji, PhD, Tetsuzo Tagawa, PhD, Yoshinao Oda, PhD, Hiroshi Honda, PhD, Yoshihiko Maehara, PhD

Publisher: Springer International Publishing

Login to get access

Abstract

Background

A relationship between sarcopenia diagnosed by skeletal muscle area (SMA) and poor prognosis in cancer patients has recently been reported. This study aimed to clarify the clinical significance of postoperatively decreased SMA in patients with early non-small cell lung cancer (NSCLC).

Methods

This study selected 101 patients with pathologic stage 1 NSCLC who had undergone pre- and postoperative (~ 1 year) computed tomography scans and lobectomy between 2005 and 2010 at Kyushu University Hospital. The post/pre ratio was defined as the postoperative normalized SMA (cm2/m2) at the 12th thoracic vertebra level divided by the preoperative normalized SMA. The cutoff value for the post/pre ratio was set at 0.9.

Results

The study classified 31 patients (30.7%) as having decreased SMA. Poor performance status (PS) was significantly associated with decreased SMA (p = 0.048). The patients with decreased SMA had a significantly shorter disease-free survival (DFS) (p < 0.001) and overall survival (OS) (p < 0.001) than the other patients. Decreased SMA was found to be an independent prognostic factor for DFS (p = 0.010) and OS (p = 0.0072). The independent risk factors for skeletal muscle loss included poor PS (PS ≥ 1) and obstructive ventilatory impairment [forced expiratory volume (FEV) 1% < 70%].

Conclusions

Skeletal muscle loss after surgery is significantly associated with postoperative poor outcomes for patients with early NSCLC. Patients with poor PS, obstructive ventilatory impairment, or both need careful support to maintain their skeletal muscle mass. Future prospective studies may clarify whether physical activity and nutritional support improve postoperative prognosis.
Literature
1.
Epidemiologic and methodologic problems in determining nutritional status of older persons. Proceedings of a conference at Albuquerque, New Mexico, 19–21 October 1988. Am J Clin Nutr. 1989;50(5 Suppl):1121–235.
2.
Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127(5 Suppl):990s–91s.CrossRefPubMed
3.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39:412–23.CrossRefPubMedPubMedCentral
4.
Tanimoto Y, Watanabe M, Sun W, et al. Association between muscle mass and disability in performing instrumental activities of daily living (IADL) in community-dwelling elderly in Japan. Arch Gerontol Geriatrics. 2012;54:e230–3.CrossRef
5.
Bahat G, Tufan A, Tufan F, et al. Cutoff points to identify sarcopenia according to European Working Group on Sarcopenia in Older People (EWGSOP) definition. Clin Nutr Edinburgh Scotland. 2016;35:1557–63.CrossRef
6.
Sanada K, Miyachi M, Tanimoto M, et al. A cross-sectional study of sarcopenia in Japanese men and women: reference values and association with cardiovascular risk factors. Eur J Applied Physiol. 2010;110:57–65.CrossRefPubMed
7.
Prado CM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care. 2009;3:269–75.CrossRefPubMed
8.
Harimoto N, Yoshizumi T, Shimokawa M, et al. Sarcopenia is a poor prognostic factor following hepatic resection in patients aged 70 years and older with hepatocellular carcinoma. Hepatol Res. 2016;46:1247–55.CrossRefPubMed
9.
Villasenor A, Ballard-Barbash R, Baumgartner K, et al. Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surviv Res Pract. 2012;6:398–406.CrossRef
10.
Suzuki Y, Okamoto T, Fujishita T, et al. Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer. Lung Cancer. 2016;101:92–7.
11.
Kim EY, Kim YS, Park I, Ahn HK, Cho EK, Jeong YM. Prognostic significance of CT-determined sarcopenia in patients with small cell lung cancer. J Thorac Oncol. 2015;10:1795–9.CrossRefPubMed
12.
Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629–35.CrossRefPubMed
13.
Stene GB, Helbostad JL, Amundsen T, et al. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol Stockh Sweden. 2015;54:340–8.CrossRef
14.
Rutten IJ, van Dijk DP, Kruitwagen RF, Beets-Tan RG, Olde Damink SW, van Gorp T. Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle. 2016;7:458–66.CrossRefPubMedPubMedCentral
15.
Miyake M, Morizawa Y, Hori S, et al. Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder. BMC Cancer.2017;17:237.CrossRefPubMedPubMedCentral
16.
Kawaguchi T, Takada M, Kubo A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol. 2010;5:620–30.CrossRefPubMed
17.
Zengin A, Pye SR, Cook MJ, et al. Associations of muscle force, power, cross-sectional muscle area, and bone geometry in older UK men. J Cachexia Sarcopenia Muscle. 2017;8:598–606.CrossRefPubMedPubMedCentral
18.
Reisinger KW, Bosmans JW, Uittenbogaart M, et al. Loss of skeletal muscle mass during neoadjuvant chemoradiotherapy predicts postoperative mortality in esophageal cancer surgery. Ann Surg Oncol. 2015;22:4445–52.CrossRefPubMedPubMedCentral
19.
Hanai T, Shiraki M, Ohnishi S, et al. Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis. Hepatol Res. 2016;46:743–51.CrossRefPubMed
20.
Miyamoto Y, Baba Y, Sakamoto Y, et al. Negative impact of skeletal muscle loss after systemic chemotherapy in patients with unresectable colorectal cancer. PLoS ONE. 2015;10:e0129742.CrossRefPubMedPubMedCentral
21.
Cao DX, Wu GH, Zhang B, et al. Resting energy expenditure and body composition in patients with newly detected cancer. Clin Nutr Edinburgh Scotland. 2010;29:72–7.CrossRef
22.
Kubo Y, Naito T, Mori K, Osawa G, Aruga E. Skeletal muscle loss and prognosis of breast cancer patients. Support Care Cancer. 2017;25:2221–2227.CrossRefPubMed
23.
Fukushima H, Nakanishi Y, Kataoka M, Tobisu KI, Koga F. Postoperative changes in skeletal muscle mass predict survival of patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. Clin Genitourin Cancer. 2016;15:e229–e238.CrossRefPubMed
24.
Ryu M, Jo J, Lee Y, Chung YS, Kim KM, Baek WC. Association of physical activity with sarcopenia and sarcopenic obesity in community-dwelling older adults: the Fourth Korea National Health and Nutrition Examination Survey. Age Ageing. 2013;42:734–40.CrossRefPubMed
25.
Bosaeus I, Rothenberg E. Nutrition and physical activity for the prevention and treatment of age-related sarcopenia. Proceed Nutr Soc. 2016;75:174–80.CrossRef
26.
Jaitovich A, Angulo M, Lecuona E, et al. High CO2 levels cause skeletal muscle atrophy via AMP-activated kinase (AMPK), FoxO3a protein, and muscle-specific Ring finger protein 1 (MuRF1). J Biol Chem. 2015;290:9183–94.CrossRefPubMedPubMedCentral
27.
Jeon YK, Shin MJ, Kim MH, et al. Low pulmonary function is related with a high risk of sarcopenia in community-dwelling older adults: the Korea National Health and Nutrition Examination Survey (KNHANES) 2008–2011. Osteoporosis Int. 2015;26:2423–9.CrossRefPubMed
28.
Bade BC, Thomas DD, Scott JB, Silvestri GA. Increasing physical activity and exercise in lung cancer: reviewing safety, benefits, and application. J Thorac Oncol. 2015;10:861–71.CrossRefPubMed
29.
Holden DA, Rice TW, Stelmach K, Meeker DP. Exercise testing, 6-min walk, and stair climb in the evaluation of patients at high risk for pulmonary resection. Chest. 1992;102:1774–9.CrossRefPubMed
30.
Woods JA, Davis JM, Kohut ML, Ghaffar A, Mayer EP, Pate RR. Effects of exercise on the immune response to cancer. Med Sci Sports Exerc. 1994;26:1109–15.PubMed
31.
Woods JA, Davis JM, Smith JA, Nieman DC. Exercise and cellular innate immune function. Med Sci Sports Exercise. 1999;31:57–66.CrossRefPubMed
32.
Okita K, Nishijima H, Murakami T, et al. Can exercise training with weight loss lower serum C-reactive protein levels? Arterioscler Thrombosis Vasc Biol. 2004;24:1868–73.CrossRef
33.
Konig D, Deibert P, Winkler K, Berg A. Association between LDL-cholesterol, statin therapy, physical activity, and inflammatory markers in patients with stable coronary heart disease. Exercise Immunol Rev. 2005;11:97–107.PubMed
34.
Mora S, Lee IM, Buring JE, Ridker PM. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA. 2006;295:1412–9.CrossRefPubMed
35.
Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17:519–31.CrossRefPubMed
Image Credits